Keryx Receives European Approval for Fexericx for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease

By: via Benzinga
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the European Commission has approved Fexeric® (ferric citrate ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.